Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706576 · ClinicalTrials.gov registry record · Phase 1
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
A Phase 1 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00706576: Completed Phase 1 study, sponsored by University of Missouri-Columbia.
NCT00706576 is a Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00706576, a Phase 1 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Hepatocellular cancer, one of the world's most deadly tumors, is associated with chronic liver injury and cirrhosis. With the increasing occurrence of viral hepatitis, the incidence of this cancer in the United States continues to rise. Surgical resection offers the only hope for cure; but sadly, few patients are candidates for surgery due to their liver disease. Liver transplant can be an effective treatment, but due to a scarcity of organs, most patients do not qualify for this therapy either. Patients who are not candidates for these procedures have very few therapeutic options as chemotherapy and radiation have little efficacy. New therapies are desperately needed. Opioid Growth Factor (OGF) inhibits the growth of a number of cancer lines in vitro by a receptor-mediated mechanism. In pancreatic cancer this phenomenon has been well defined not only in vitro but in animal models. Based upon these findings, a phase I trial has been conducted demonstrating that OGF can be administered safely to patients with pancreatic cancer. The investigators hypothesize that administration of OGF will inhibit the course of cancer progression in human subjects with unresectable hepatocellular cancer and cirrhosis. As a first step in testing this hypothesis, the investigators propose a phase I trial to study the toxicity and pharmacokinetics of this therapy in patients suffering from inoperable hepatocellular cancer and cirrhosis.
Primary Outcome
primary outcome variable is toxicity and or tolerance to opioid growth factor in patients with hepatocellular cancer
Interventions
- DRUG Infusion of opioid growth factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
What the finished NCT00706576 record still lists
NCT00706576 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Infusion of opioid growth factor is the first listed.
NCT00706576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00706576 about?
NCT00706576 is a clinical study titled "Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor". Hepatocellular cancer, one of the world's most deadly tumors, is associated with chronic liver injury and cirrhosis. With the increasing occurrence of viral hepatitis, the incidence of this cancer in the United States continues to rise. Surgical resection offers the only hope for cure; but sadly, fe...
What is the current status of trial NCT00706576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2008-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00706576?
The interventions under investigation include: Infusion of opioid growth factor (DRUG).
Who is sponsoring clinical trial NCT00706576?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00706576's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia